Home Meetings Highlights

Highlights

Summaries and high points from meetings about lung cancer and other thoracic neoplasms.

Latest

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

lungcanc

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib

PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC

Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy

Single-Agent Pembrolizumab Active Against STK11– and KEAP1– Mutated NSCLC According to KEYNOTE-042 Analysis

The Long Road Home

lungcanc

EGFR-Targeted Therapy: A New Beginning

lungcanc

2017 Lung Cancer SPORE Workshop

lungcanc

Lung Cancer 360 Forum Overview: C.A.I.R.O Journal Club’s Fourth Anniversary

lungcanc

Lung Cancer Immunotherapy Meeting to Discuss New Topics, Emerging Themes

lungcanc

5th AACR-IASLC International Joint Conference: Translational Progress through Basic Research

lungcanc

Studies Indicate Expanding Benefit of Checkpoint Inhibitors

lungcanc

Bronchoscopy Ultrasound and Navigational Bronchoscopy Finally Arrive in Peru

lungcanc

IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology

lungcanc

IASLC WCLC 2017 Presidential Symposium Presents Leading Lung Cancer Research

lungcanc

123 4 Page 2 of 4

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib